drugset / Trial / NCT06938503
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).
Timeline
- Start
- 2025-04-21
- Primary completion
- 2028-04-25
- Completion
- 2028-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | — |